Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol-Myers Squibb news coverage encompasses regulatory developments, clinical trial results, product launches, business transactions, and corporate initiatives. The company's activities across oncology, hematology, immunology, cardiovascular, and neuroscience generate frequent updates that impact stakeholders in the healthcare and investment communities.
Regulatory announcements represent significant news events for Bristol-Myers Squibb, including approvals of new medicines, expanded indications for existing products, and regulatory submissions in various markets. These milestones reflect the progression of the company's pipeline from clinical development through regulatory review to market authorization. Priority review designations, breakthrough therapy designations, and orphan drug designations also generate news coverage as indicators of regulatory progress.
Clinical trial data releases occur at medical conferences, in peer-reviewed publications, and through corporate announcements. Results from pivotal trials evaluating new medicines or expanded uses of approved products receive particular attention from the medical community and investors. The company's extensive clinical trial portfolio across multiple therapeutic areas produces a steady stream of data readouts that inform understanding of product profiles and market potential.
Business development activities including acquisitions, licensing agreements, research collaborations, and strategic partnerships shape Bristol-Myers Squibb's long-term direction. These transactions can bring new assets into the pipeline, provide access to novel technologies, or establish collaborations with academic institutions and biotechnology companies. Divestitures and portfolio prioritization decisions also generate news coverage.
Commercial performance updates occur through periodic financial reporting and corporate presentations. These updates provide insight into product uptake, market penetration, competitive dynamics, and the impact of healthcare policy changes on business results. Manufacturing capacity expansions, supply chain developments, and commercial launches in new geographic markets represent additional categories of business news.
Corporate initiatives related to sustainability, patient access, health equity, research funding, and community engagement reflect broader aspects of Bristol-Myers Squibb's operations beyond drug development and commercialization. Leadership changes, organizational restructuring, and strategic priority shifts also contribute to news flow.
Bristol Myers Squibb (NYSE: BMY) has expanded its direct-to-patient program by introducing the new BMS Patient Connect platform, offering significant discounts on two key medications. Eliquis (apixaban) will be available at over 40% below list price, while Sotyktu (deucravacitinib) will be offered at more than 80% discount starting January 2026.
The initiative aims to improve medication accessibility and affordability across all 50 states and Puerto Rico for eligible cash-paying patients. Sotyktu, a first-in-class TYK2 inhibitor, is used to treat moderate-to-severe plaque psoriasis in adults. The platform will provide patient support resources and may include additional BMS medicines in the future.
Bristol Myers Squibb (NYSE:BMY) announced positive interim results from its Phase 3 EXCALIBER-RRMM study of iberdomide, a novel CELMoD™ therapy, in combination with daratumumab and dexamethasone for relapsed or refractory multiple myeloma (RRMM).
The study achieved a statistically significant improvement in minimal residual disease (MRD) negativity rates compared to the control arm. The trial will continue to evaluate other endpoints including progression-free survival and overall survival. The safety profile remained consistent with previous studies.
Iberdomide represents the first of a new class of medicines called CELMoDs, potentially establishing a new foundation for multiple myeloma treatment. The company plans to discuss these results with health authorities.
Bristol Myers Squibb (NYSE: BMY) has scheduled its third quarter 2025 financial results announcement for October 30, 2025. The company will host a conference call with the investment community at 8:00 a.m. ET to discuss the results.
Investors and the public can access the live webcast at investor.bms.com, where related materials will be available before the call. A replay will be accessible approximately three hours after the conference concludes on the same platform.
Bristol Myers Squibb (NYSE: BMY) has announced its latest dividend declarations. The company's Board of Directors has declared a quarterly dividend of $0.62 per share on common stock, payable on November 3, 2025, to stockholders of record as of October 3, 2025.
Additionally, the Board declared a quarterly dividend of $0.50 per share on the company's $2.00 convertible preferred stock, which will be payable on December 1, 2025, to stockholders of record as of November 4, 2025.
Bristol Myers Squibb (NYSE:BMY) announced its participation in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum scheduled for September 23, 2025. The company will engage in a fireside chat starting at 9:40 a.m. ET.
Investors and the public can access the session through the company's investor relations website at investor.bms.com. An archived recording will be made available after the event's conclusion.
Bristol Myers Squibb (NYSE:BMY) presented results from COLLIGO-HCM, a global real-world study of Camzyos (mavacamten) at the ESC Congress 2025. The study demonstrated the drug's effectiveness in treating obstructive hypertrophic cardiomyopathy (oHCM) across a diverse patient population from four continents.
Key findings showed that 59.9% of patients achieved NYHA class improvement by week 24, with 94.4% of patients reaching NYHA class II or below at 24 weeks. By week 36, 90.3% of patients achieved target LVOT gradients. The safety profile remained consistent with clinical trials, with only 4% requiring temporary interruption due to LVEF concerns.
The study is part of the larger WAYFARER-HCM program, spanning 7 countries and over 3,000 patients, reinforcing Camzyos' position as a standard of care for NYHA class II-III symptomatic oHCM patients.
Bristol Myers Squibb (NYSE: BMY) announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference scheduled for September 8, 2025. The company will engage in a fireside chat starting at 8:30 a.m. ET.
The session will be accessible to investors and the public through the company's investor relations website at investor.bms.com, with an archived recording available after the event.
Bristol Myers Squibb (NYSE: BMY) announced new clinical and real-world data presentations for its cardiovascular portfolio at the upcoming European Society of Cardiology Congress 2025 in Madrid. The presentations will focus on Camzyos (mavacamten), the first and only approved cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Key highlights include real-world outcomes from COLLIGO-HCM study across five countries, a pooled analysis of four Phase 3 studies on Camzyos monotherapy, and topline results from ODYSSEY-HCM, the largest Phase 3 trial in non-obstructive HCM patients. The congress will take place from August 29 to September 1, 2025, featuring multiple presentations on Camzyos's efficacy, safety, and real-world effectiveness.
Bristol Myers Squibb (NYSE: BMY) and SystImmune announced that their drug izalontamab brengitecan (iza-bren) has received Breakthrough Therapy Designation (BTD) from the FDA for treating advanced EGFR-mutated non-small cell lung cancer (NSCLC) in patients who progressed after EGFR TKI and platinum-based chemotherapy.
Iza-bren is a first-in-class bispecific antibody-drug conjugate (ADC) targeting both EGFR and HER3 receptors. The BTD was based on promising efficacy and safety data from three ongoing clinical trials: BL-B01D1-101, BL-B01D1-203 (in China), and the global BL-B01D1-LUNG-101 study.
This development addresses a significant unmet need, as NSCLC represents 80% of lung cancer cases, with 10-15% of Western and up to 50% of Asian patients having EGFR mutations. Current treatments typically show resistance after 18 months, highlighting the need for more effective therapies.
Bristol Myers Squibb (NYSE: BMY) announced that the FDA has accepted their supplemental biologics license application (sBLA) for Breyanzi with Priority Review for treating adult patients with relapsed or refractory marginal zone lymphoma (MZL). The PDUFA goal date is set for December 5, 2025.
The application is based on results from the MZL cohort in TRANSCEND FL, a Phase 2 study presented at ICML 2025. If approved, Breyanzi would become the first and only CAR T cell therapy for MZL, addressing a significant unmet need in patients who have received at least two prior lines of systemic therapy.
This potential approval would mark Breyanzi's fifth cancer type indication, building on its existing approvals in LBCL, CLL/SLL, follicular lymphoma, and mantle cell lymphoma.
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
